ELIXIR Belgium

  • offers specialized bioinformatics resources accelerating research in life-science. These include databases, data resources, tools, workflows, …that have applications in plant sciences, human health and proteomics. We aim to extend the functionality and compatibility of the resources developed by different Belgian research groups.
  • focusses on data management, data analysis platforms and training. We provide an ELIXIR template and guidance to fill in data management plans in DMPonline.be. The research data management tool, DataHub is in full development and enables researchers to manage their research data and produce FAIR data by design. Recommended best practises and guidelines for research data management are available in our RDM Guide. To facilitate reproducible analysis, we have set up the centrally managed Galaxy instance UseGalaxy.be. Our training portfolio can be consulted on the Training page.
  • supports COVID-19 research. To encourage and assist researchers to make scientific data available, we implemented a tool to simplify the submission of SARS-CoV-2 sequencing data to the European Nucleotide Archive (ENA). This video illustrates how to use the tool. A complete overview of our COVID-19 related activities can be found on the dedicated ELIXIR interactive map.

A call for Node Services is launched every two years. Services that are positively evaluated by the Scientific Advisory Board are added to ELIXIR Belgium’s Service Delivery Plan. Node Services are labelled as important resources produced by the Belgian bioinformatics community. Below, an overview of all ELIXIR Belgium services is given - Node Services have the respective tag. The next call for Node Services is scheduled for April 2022. A complete service list of all ELIXIR Nodes can be found on this link.  


Logo useGalaxy.be

Usegalaxy.be is a public Galaxy instance enabling reproducible data analysis through workflows. Next to providing support for reproducible science, the platform facilitates sharing of data and results, and removes the need for users to install tools.

UseGalaxy.be was developed by ELIXIR Belgium and has been released for public use in 2019. The platform is hosted on the Flemish Supercomputer Centre.

Globally, Galaxy is broadly used in life sciences and beyond. Publications referring to Galaxy can be found here. In March 2020, the Belgian Galaxy instance was used to re-analyse available COVID-19 data and assess the reproducibility of initial papers on the COVID-19 genome. The joint paper by Galaxy teams from the United States, Australia and ELIXIR, indicated the importance of open access data and open reproducible analytics for fast and efficient response to global health crises as the COVID-19 pandemic.

Service Tags


Logo VariantDB

VariantDB is a web-based interactive annotation and filtering platform that automatically annotates variants with allele frequencies, functional impact, pathogenicity predictions and pathway information. VariantDB allows filtering by all annotations, under dominant, recessive or de novo inheritance models. VariantDB is therefore a user-friendly and powerful tool to help in the interpretation of NGS data.

VariantDB was developed at the University of Antwerp and published in Genome Medicine (manuscript).


Logo WiNGS

WiNGS is being developed to succeed NGS-Logistics, the genomics data sharing platform established at KULeuven. The NGS-Logistics platform is currently deployed at 6 of the 8 genetic centres in Belgium and lets users identify clinically relevant mutations at other genetic centres. Its scope is similar but broader than the more recent Beacon project of the Global Alliance for Genomics and Health (GA4GH) and ELIXIR Europe, which provides a framework for public web services for variant discovery against distributed genomic data collections. The ELIXIR Belgium Human Data consortium, led by KULeuven, has been participating in the ELIXIR Beacon project and maintains a Belgian Beacon node.

The WiNGS (Widely integrated NGS) platform holds significant scalability improvements to tackle the complexity of analysing of Whole-Genome Sequencing (WGS) data. Because of the sensitivity of patient genomes and GDPR requirements, enhanced access control and privacy protection for this integrated platform will be developed. The first manuscript of the platform can be downloaded here.